Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 800-253-4 | CAS number: 1419212-73-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
Rats (12/sex/dose) received the test substance by gavage at 0, 100, 300 and 1000 mg/kg bw daily for at least 6 weeks (including two weeks prior to mating, through mating, pregnancy and early lactation for females). The test design followed was according to OECD 422.
Two males died due to intubation errors. No treatment related effects were found on clinical signs, body weight (gain), food and water consumption, haematology, clinical chemistry, behavioural assessments, organ weights macroscopic investigations and histology.
No effects were reported related to mating, fertility and reproduction (sperm quality, number corpora lutea, number implantation sites, pre- and postimplantion losses or sex ratio). No effects were found on pregnancy rate, gestation length, viability of the offspring, offspring weight or any other parameters observed.
Based on the above mentioned the NOAEL for systemic effects in parental animals is 1000 mg/kg bw. The NOAEL for effects on reproduction and development is 1000 mg/kg bw.
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 16 Oct 2014 to
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study according to OECD 422 under GLP
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories U.K. Ltd., Blackthorn, Bicester, Oxon, UK
- Strain: Wistar Han™:RccHan™
- Age at study initiation: ca.12 weeks
- Weight at study initiation: Males: 322-378 g; Females: 197-222 g
- Fasting period before study: none
- Housing: Pretest and premating period: 4 animals/cage; Mating period: one male and one female/cage; Postmating: males 4/cage, females individually
- Diet: Rodent 2018C Teklad Global Certified Diet (Harlan Laboratories U.K. Ltd., Oxon, UK) ad libitum
- Water: Tap water in bottles ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 50 ± 20%
- Air changes (per hr): ≥15/hr
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- arachis oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: every 14 days stored at ca. 4 °C in the dark
VEHICLE: Arachis oil BP
- Justification for use and choice of vehicle (if other than water): not indicated
- Concentration in vehicle: 0, 25, 75 and 250 mg/mL
- Dose volume: 4 mL/kg - Details on mating procedure:
- - M/F ratio per cage: 1/1
- Length of cohabitation: 1-4 days
- Proof of pregnancy: vaginal plug or sperm in vaginal smear referred to as day 0 of pregnancy
- After successful mating each pregnant female was caged individually - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Actual concentrations in the test substance formulations were 105-112% of nominal
System: HPLC-MS
HPLC System: HPLC Agilent 1200 MSD
Column: Symmetry C18: 50 mm*3.0 mm: 3.5 um
Column temperature: 30 °C
Detection method: MS/SIM
Injection volume: 10 µL
Mobile Phase: 0.05% ammonium formate in water with 0.1% formic acid methanol (30/70 v/v)
Column flow rate: 0.5 mL/min
Retention time: Approx. 2.5-15 min
Calibration solution: 0.05 g of the test substance was weighed in a 100-mL flask and brought to volume with methanol (0.5 mg/mL). Aliquots were further diluted with methanol to a concentration of 0.01 mg/mL
HPLC-MS gave several peaks with one considered to be representative (area changes with known concentration). Linearity of the system demonstrated over 0-0.0177 mg/mL (R2 of fit 0.997).
Analysis for accuracy of preparation, homogenicity and stability:
accuracy of preparation: 98-104 % of nominal (3.68-3.92 mg/g and 250-253 mg/g fortification)
homogenicity: 95.6 ± 1.2% (at 3.75 mg/mL) and 102 ± 0.4% (at 250 mg/mL)
stability : mean recovery 97-98% over 17 days - Duration of treatment / exposure:
- Males: two weeks prior to mating, during mating and at least up to and including the day before sacrifice (at least a total of 42 days).
Females: two weeks prior to mating, during mating and at least up to and including the day before sacrifice (day 4 post partum). - Frequency of treatment:
- daily
- Remarks:
- Doses / Concentrations:
0, 100, 300 and 1000 mg/kg bw
Basis:
nominal conc. - No. of animals per sex per dose:
- 12/sex
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Dose selection rationale: based on a 14-day dose-range-finding toxicity study in rats (Harlan Laboratories Study 41403024, Fourteen Day Repeated Dose Oral (Gavage) Range-Finding Toxicity Study in the Rat), using dose levels of 0, 500, 750 and 1000 mg/kg/day.
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes (Gait, Hyper/Hypothermia, Tremors, Skin color, Twitches, Respiration, Convulsions, Palpebral closure, Bizarre/Abnormal/Stereotypic behavior, Urination, Salivation, Defecation, Pilo-erection, Transfer arousal, Exophthalmia, Tail elevation, Lachrymation)
- Time schedule: once weekly in a standard arena
BODY WEIGHT: Yes
- Time schedule for examinations:
P males: at pretest and weekly during the pre-pairing, pairing period and post-pairing period.
P females: at pretest and weekly during the pre-pairing, daily during the pairing period and on day 0, 7, 14 and 20 post-coitum and day 1 and 4 post-partum.
FOOD CONSUMPTION : yes
- Time schedule for examinations:
P males: weekly during the pre-pairing and post-pairing period.
P females: weekly during the pre-pairing period and days 0-7, 7-14, 14-21 post coitum and days 1-4 post partum.
WATER CONSUMPTION: yes
- Time schedule for examinations:
P-males and females daily during pre-pairing
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood:
5 selected males: on day 42 of treatment (on day of sacrifice)
5 selected females: on day 5 post partum (on day of sacrifice)
- Anaesthetic used for blood collection: No
- Animals fasted: No
- Parameters checked: Erythrocyte count, Hemoglobin, Hematocrit, Mean corpuscular volume, Mean corpuscular hemoglobin, Mean corpuscular hemoglobin concentration, Platelet (thrombocyte) count, Reticulocyte count, Total leukocyte count, Differential leukocyte count (Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils), prothrombine time, APTT.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood:
5 selected males: on day 42 of treatment (on day of sacrifice)
5 selected females: on day 5 post partum (on day of sacrifice)
- Anaesthetic used for blood collection: No
- Animals fasted: No
- Parameters checked: Urea, Calcium, Glucose, Inorganic phosphorus, Total protein, Aspartate aminotransferase,Albumin Alanine aminotransferase, Albumin/Globulin ratio, Potassium, Total cholesterol,Chloride, Total bilirubin, Bile acids
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes post-partum
- Battery of functions tested: Motor activity, Grip strength (hind and fore limb), Grasp response, Touch escape, Vocalization, Pupil reflex, Toe pinch, Blink reflex, Tail pinch, Startle reflex, Finger approach.
Date of pairing, Date of mating, Date and time of observed start of parturition, Date and time of observed completion of parturition - Sperm parameters (parental animals):
- Detailed qualitative examination of the testes was undertaken, taking into account the tubular stages of the spermatogenic cycle. The examination was conducted in order to identify treatment-related effects such as missing germ cell layers or types, retained spermatids, multinucleated or apoptotic germ cells and sloughing of spermatogenic cells into the lumen.
- Litter observations:
- PARAMETERS EXAMINED
The following parameters were examined in offspring:
number and sex of pups, live births, postnatal mortality, weight (day 1 and 4), clinical signs, presence of gross anomalies, rightening reflex - Postmortem examinations (parental animals):
- GROSS PATHOLOGY: Yes : on all animals
HISTOPATHOLOGY: Yes : on 5 animals/sex of the control and high dose group
Adrenals Muscle (skeletal) , Aorta (thoracic), Ovaries, Bone & bone marrow (femur including stifle joint), Bone & bone marrow (sternum), Brain (including cerebrum, cerebellum and pons), Prostate, Pancreas, Pituitary, Caecum, Rectum, Jejunum, Colon, Duodenum, Ileum (including Peyer’s patches) Coagulating gland, Salivary glands (submaxillary), Seminal vesicles, Epididymides, Skin (hind limb), Esophagus, Sciatic nerve, Spinal cord (cervical, mid-thoracic and lumbar), Eyes, Spleen, Heart, Stomach, Thyroid/parathyroid, Trachea, Kidneys, Testes , Liver, Thymus, Lungs (with bronchi), Urinary bladder, Lymph nodes (mandibular and mesenteric), Uterus/Cervix, Mammary gland, Vagina, Gross lesions
on all animals/sex from the control and the high dose group: reproductive organs, mammary gland and pituitary ; Uterus examined for implantation sites
Organ weights:
on 5 animals/sex of the control and high dose group: Adrenals, Kidneys, Brain, Liver, Thymus, Thyroid and parathyroids, Heart, Spleen
on all animals: Testes, Prostate, Seminal vesicle, Epididymides, Ovaries, Uterus(with Cervix), Pituitary - Postmortem examinations (offspring):
- GROSS NECROPSY
- Statistics:
- Provantis Tables and Statistics Module including
•ANOVA
•Bartlett test
•Williams test or Shirley test
•Dunnett's or Steel test
•Student's t-test or Mann Whitney U-test
plus additional tests when the above mentioned methods were not analyzed by the Provantis data capture system - Reproductive indices:
- Percentage Mating (%) = (Number of females mated/Number of females paired) x 100
Pregnancy rate (%) = (Number of females achieving pregnancy/Number of females mated) x 100
Gestation Index (%) = (Number of females with live pups/Number of females pregnant) x 100 - Offspring viability indices:
- Viability index (%) = (Number of alive pups on Day 4/Number of offspring alive on Day 1)x 100
Live birth index (%) = (Number of offspring alive on Day 1/ Number of offspring delivered)x 100
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Salivation in males and females at 1000 mg/kg bw (related to test substance palatability)
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- 2 Males (1 at 300 and 1 at 1000 mg/kg bw) died due to intubation errors
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Males: 300 and 1000 mg/kg bw: Hb significantly decreased: MCHC (significantly) decreased; 1000 mg/kg bw: increased WBC/leukocytes
Females: 1000 mg/kg bw: increased WBC/significantly increased neutrophiles
All effects were within historical background ranges
: - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Males: 300 and 1000 mg/kg bw: significantly decreased inorganic phosphorus
Females: 300 and 1000 mg/kg bw: (significantly) decreased inorganic phosphorus; at 1000 mg/kg: significantly increased TP and cholesterol
All effects were within historical background ranges - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- MATING INDEX: 100% at all doses
PREGNANCY RATE: 100% at all doses
PARTURATION INDEX: 100% at all doses - Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects
- Clinical signs:
- not specified
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- VIABILITY INDEX (OFFSPRING): 100%, 99.3%, 99.3%, 98.6% at 0, 100, 300 and 1000 mg/kg bw
LIVE BIRTH INDEX (OFFSPRING): 100%, 97.6%, 98.5%, 100% at 0, 100, 300 and 1000 mg/kg bw - Body weight and weight changes:
- no effects observed
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not specified
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- no treatment related effects in rightening reflex
- Developmental immunotoxicity:
- not examined
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects
- Reproductive effects observed:
- not specified
- Conclusions:
- The NOAEL on reproductive and developmental effects is 1000 mg/kg bw.
The NOAEL for maternal toxicity is 1000 mg/kg bw - Executive summary:
Rats (12/sex/dose) received the test substance by gavage at 0, 100, 300 and 1000 mg/kg bw daily for at least 6 weeks (including two weeks prior to mating, through mating, pregnancy and early lactation for females). The test design followed was according to OECD 422.
Two males died due to intubation errors. No treatment related effects were found on clinical signs, body weight (gain), food and water consumption, haematology, clinical chemistry, behavioural assessments, organ weights macroscopic investigations and histology.
No effects were reported related to mating, fertility and reproduction (sperm quality, number corpora lutea, number implantation sites, pre- and postimplantion losses or sex ratio). No effects were found on pregnancy rate, gestation length, viability of the offspring, offspring weight or any other parameters observed.
Based on the above mentioned the NOAEL for systemic effects in parental animals is 1000 mg/kg bw. The NOAEL for effects on reproduction and development is 1000 mg/kg bw.
Reference
2 Males (1 at 300 and 1 at 1000 mg/kg bw) died due to intubation errors
Salivation in males and females at 1000 mg/kg bw (related to test substance palatability)
BODY WEIGHT AND WEIGHT GAIN: No treatment related effects
FOOD CONSUMPTION : No treatment related effects
WATER CONSUMPTION : No treatment related effects
HAEMATOLOGY:
Males: 300 and 1000 mg/kg bw: Hb significantly decreased: MCHC (significantly) decreased; 1000 mg/kg bw: increased WBC/leukocytes
Females: 1000 mg/kg bw: increased WBC/significantly increased neutrophiles
All effects were within historical background ranges
CLINICAL CHEMISTRY:
Males: 300 and 1000 mg/kg bw: significantly decreased inorganic phosphorus
Females: 300 and 1000 mg/kg bw: (significantly) decreased inorganic phosphorus; at 1000 mg/kg: significantly increased TP and cholesterol
All effects were within historical background ranges
NEUROBEHAVIOUR: No treatment related effects
ORGAN WEIGHTS: No treatment related effects
GROSS PATHOLOGY: No treatment related effects
HISTOPATHOLOGY: No treatment related effects
SPERMATOGENESIS: No treatment related effects
IMPLEMENTATION SITES/CORPORA LUTEA: No treament related effects
MATING INDEX: 100% at all doses
PREGNANCY RATE: 100% at all doses
PARTURATION INDEX: 100% at all doses
LIVE BIRTH INDEX (OFFSPRING): 100%, 97.6%, 98.5%, 100% at 0, 100, 300 and 1000 mg/kg bw
BEHAVIOURAL EFFECTS (OFFSPRING): no treatment related effects in rightening reflex
BODY WEIGHT (OFFSPRING): no treatment related effects
SEX RATIO (OFFSPRING): no treatment related effects
MACROSCOPY (OFFSPRING): no treatment related effects
Averages maternal animals
pregnancy: 12,12,12, 12 at 0, 100, 300 and 1000 mg/kg bw
corpora lutea: 13.3, 13.4, 12.3, 13.7 at 0, 100, 300 and 1000 mg/kg bw
implants: 12.8, 12.9, 12.0, 13.0 at 0, 100, 300 and 1000 mg/kg bw
pre-coital time: 1 -4 days, no treatment related effect
gestation length: 22 -23.5 days no treatment related effects
females with live offspring (day 1-4): 12, 12, 12,12 at 0, 100, 300 and 1000 mg/kg bw
Percentage Mating: 100% at all dose levels
Pregnancy rate: 100% at all dose levels
Gestation Index: 100% at all doselevels,
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
No effects on reproduction and/or fertility were found at any of the doses tested.
Justification for selection of Effect on fertility via oral
route:
Guideline study under GLP
Effects on developmental toxicity
Description of key information
Rats (12/sex/dose) received the test substance by gavage at 0, 100, 300 and 1000 mg/kg bw daily for at least 6 weeks (including two weeks prior to mating, through mating, pregnancy and early lactation for females). The test design followed was according to OECD 422.
Two males died due to intubation errors. No treatment related effects were found on clinical signs, body weight (gain), food and water consumption, haematology, clinical chemistry, behavioural assessments, organ weights macroscopic investigations and histology.
No effects were reported related to mating, fertility and reproduction (sperm quality, number corpora lutea, number implantation sites, pre- and postimplantation losses or sex ratio). No effects were found on pregnancy rate, gestation length, viability of the offspring, offspring weight or any other parameters observed.
Based on the above mentioned the NOAEL for systemic effects in parental animals is 1000 mg/kg bw. The NOAEL for effects on reproduction and development is 1000 mg/kg bw.
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
No effects on development were found at any of the doses tested.
Justification for selection of Effect on developmental
toxicity: via oral route:
OECD 422 study according to the guideline under GLP available
Justification for classification or non-classification
The available data on toxicity to reproduction and developmental toxicity of the test substance do not meet the criteria for classification according to Regulation (EC) 1272/2008 or Directive 67/548/EEC, and are therefore conclusive but not sufficient for classification.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.